[Regional ventricular function before and after sublingual administration of nitroglycerin in patients with recent myocardial infarction in the subacute and chronic stage].
Seven patients with a recent myocardial infarction and mostly normal left ventricular end-diastolic pressure were investigated by radionuclide ventriculography after 3-4 days and three weeks before and after 1.6 mg nitroglycerin. Between day 3-4 and the third week global ejection fraction (EF) rose insignificantly (p greater than 0.05) from 31 +/- 4 to 37 +/- 6 percent. The regional EF in the non infarcted area remained nearly stable (74 +/- 5 to 85 +/- 13 relative percent, p greater than 0.05). However, the EF in the infarcted area rose from 22 +/- 9 to 38 +/- 11 relative percent (p less than 0.05 percent). On day 3-4 nitroglycerin induced a clear increase of the EF in the infarcted area from 22 +/- 9 to 35 +/- 11 relative percent (p less than 0.05). The global EF and the EF in the non infarcted area remained nearly constant (global EF from 31 +/- 4 to 34 +/- 5 percent, EF in the non infarcted area from 74 +/- 5 to 77 +/- 7 relative percent; p greater than 0.05). Three weeks after myocardial infarction 1.6 mg nitroglycerin did not produce a significant alteration of the ejection fraction (slight increase of the global EF from 37 +/- 6 to 40 +/- 6, the regional EF in the infarcted area from 38 +/- 11 to 48 +/- 11 relative percent and from 85 +/- 13 to 90 +/- 11 relative percent in the non infarcted area; p greater than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
D002302:Cardiac Output / Q000187:drug effects; D002908:Chronic Disease; D003327:Coronary Disease / Q000188:drug therapy; D004562:Electrocardiography; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects*; D009203:Myocardial Infarction / Q000188:drug therapy*; D005996:Nitroglycerin / Q000627:therapeutic use*; D011669:Pulmonary Wedge Pressure / Q000187:drug effects
D005996:Nitroglycerin
Regionale Ventrikelfunktion vor und nach sublingualer Gabe von Nitroglycerin bei Patienten mit frischem Herzinfarkt im subakuten und chronischen Stadium.